Oracle Strikes the Right Balance Between Industry Specificity and Functionality According to Datamonitor
REDWOOD SHORES, Calif. 07-JAN-2008 05:00 AM Oracle today announced that Datamonitor, a leading provider of online data, analytic and forecasting platforms for key vertical sectors, has recognized Oracle as a leader in customer relationship management (CRM) applications for the life sciences industry. According to Datamonitor’s Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Industry (Competitor Focus), Oracle combines robust CRM technology with extensive market impact in the pharmaceutical sector.
According to the report, Oracle is recognized as the leading vendor in the categories of market impact, technology assessment and end-user sentiment, which propels it to a top position on the shortlist of CRM vendors in the pharmaceutical industry. In addition, the report – which also evaluated Cegedim Dendrite, Salesforce.com, StayinFront and Verticals onDemand – rates Oracle’s Siebel CRM as the most recognized solution among surveyed respondents and the solution that received the highest scores across six out of eight end-user categories, including product quality, portfolio depth and financial stability.
“Because Siebel CRM 8 balances industry expertise with a robust enterprise-class technology that is customizable to every type of end user in pharmaceutical sales and marketing, life science companies should shortlist Oracle when considering a CRM product,” wrote Markella Kordoyanni, Datamonitor analyst for Pharmaceutical Technology, and Nicole Engelbert, Datamonitor lead analyst for Vertical Markets Technology, in the report. “Siebel CRM 8 is a harmonious fit for companies looking for enterprise-wide, global deployment of a comprehensive ‘out-of-the-box’ solution that offers a 360-degree view if its customers,” the report continues.
“Oracle understands the value of tailoring our applications to the distinct industries we serve. This is particularly important in the life sciences industry, which faces a set of unique competitive and regulatory challenges,” said Neil de Crescenzo, group vice president, Healthcare and Life Sciences, Oracle. “Datamonitor’s Decision Matrix for CRM in the pharmaceutical industry – along with the fact that 20 of the top 20 life sciences organizations run Oracle applications – underscores Oracle’s commitment to and success in delivering industry-specific functionality to our life sciences customers.”
The Decision Matrix report provides guidance and recommendations for companies planning to implement a CRM solution – positioning vendors in one of three categories: 1) shortlist – defined in the report as vendors with an established, commanding market position with a product that is widely accepted as best of breed; 2) consider – defined as vendors that offer competitive functionality and high performance at affordable costs, and should be considered as part of the technology selection process; and 3) explore – defined as vendors with less broad applicability and limited functionality that may meet specific requirements.
To provide a comprehensive view of the competitive landscape of CRM solutions, Datamonitor surveyed nearly 300 end users in the pharmaceutical industry. The research provider also conducted in-depth briefings with the vendors profiled in the report and used secondary research sources to provide information and validate the report.
To view a summary of Datamonitor’s Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Industry (Competitor Focus), visit http://www.oracle.com/corporate/analyst/reports/ent_apps/crm/datamonitor-crm-pharmaceutical.pdf. The full report is available for purchase at www.Datamonitor.com (Report Code DMTC 2133).
Oracle (NASDAQ: ORCL) is the world’s largest enterprise software company. For more information about Oracle, visit our Web site at www.oracle.com.
Oracle is a registered trademark of Oracle Corporation and/or its affiliates. Other names may be trademarks of their respective owner.
Reference herein to third party content, including analysis, opinions, predictions and statements, does not constitute or imply Oracle’s endorsement of or concurrence with such content.